Vanda Pharmaceuticals (NASDAQ:VNDA) is scheduled to announce Q2 earnings results on Thursday, July 31st, before market open. The consensus EPS Estimate is -$0.36 and the consensus revenue estimate is ...

The terms of Cycle Pharma's proposal are "economically identical" to the previously evaluated and rejected offer, Vanda said in a statement. Cycle Pharma's $8 per share proposal is an 80% premium ...

Vanda acquired rights to U.S. and Canadian rights to PONVORY ® from Actelion Pharmaceuticals Ltd., a Johnson& Johnson Company. PONVORY ® is approved by the U.S. Food and Drug Administration and ...

HC Wainwright sets an $18 target on Vanda Pharmaceuticals amid a 30% discount to cash reserves. Vanda's portfolio could reach key clinical and regulatory milestones within 6–18 months.

May 17, 2022 9:50 AM ET Vanda Pharmaceuticals Inc. (VNDA) Stock VNDA 2 Comments 1 Like BioSci Capital Partners 15.96K Follower s ...

Vanda Pharmaceuticals (NASDAQ: VNDA) looks to be a fundamentally strong, early-stage biotech investment opportunity based on my analysis, which is currently trading at a 42% discount to its early ...

Vanda Pharmaceuticals is advancing clinical trials for several new drugs that, if approved, would mean new revenue streams for the D.C. company.

Vanda Pharmaceuticals Inc VNDA Stock XNAS Rating as of Jul 28, 2025 Summary Chart News Price vs Fair Value Sustainability Trailing Returns Key Metrics Financials Valuation Dividends Ownership ...

What happened Shares of Vanda Pharmaceuticals (NASDAQ: VNDA) fell more than 19% today after the company announced it was pursuing legal action against the U.S. Food and Drug Administration.

Vanda Pharmaceuticals has seen an increase in net product sales this year — in a landscape the Covid-19 pandemic has generally challenged and after a rocky period for the D.C. biotech.